More Mayne Pharma Group Ltd. news
Mayne Pharma Group Ltd.ASX: MYX

Appendix 4E and Statutory Accounts

Aug 25, 2022 at 10:37 PM EDT · Issued by Mayne Pharma Group Ltd.

Filed with ASX · Aug 25, 2022 at 10:37 PM EDT · 76 pages · English

On 6ix: 6ix.com/news/appendix-4e-and-statutory-accounts

Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26↗

Mayne Pharma Group Ltd. on 6ix

In the deck

  • Mayne Pharma Group — Investor Presentation (August 2022)34 slidesAug 26, 2022

Earlier from Mayne Pharma

  • Mayne Pharma Group: CEO announces plan to retireAug 19, 2022
  • Mayne Pharma announces sale of Metrics Contract ServicesAug 9, 2022
  • Mayne Pharma and Mithra announce FDA approval of Haloette, a generic version of NuvaringAug 7, 2022
  • Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS and expand access to birth controlAug 1, 2022
  • Mayne Pharma Group Limited and Mithra Pharmaceuticals - NEXTSTELLIS ORAL CONTRACEPTIVE NOW AVAILABLE IN AUSTRALIAJul 27, 2022

Later from Mayne Pharma

  • 2022 Full Year Media ReleaseAug 25, 2022
  • 2022 Full Year Investor PresentationAug 25, 2022
  • Mayne Pharma Group - non-executive Director appointment and retirementAug 31, 2022
  • Mayne Pharma appoints new CEOSep 27, 2022
  • Mayne Pharma - appointment of chief executive officer and Managing DirectorSep 29, 2022
All Mayne Pharma news releases↗

Follow Mayne Pharma into a list and get an email when it puts out news.

Follow Mayne Pharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer